Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CTSA | P10619 | 6/20 | 0.43 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | BCR | P11274 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5419505 | 0.90 | CTSA (0.52) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL5425591 | 0.85 | HPGD (0.48) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL5426082 | 0.85 | HPGD (0.46) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL5440369 | 0.83 | HPGD (0.55) | HPGDALDH1A1MAPTLMNACTSA | |
| SCHEMBL5430302 | 0.81 | HPGD (0.49) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL29933950 | 0.79 | MKNK1 (0.51) | CTSA | |
| SCHEMBL5424646 | 0.77 | HPGD (0.47) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL5419503 | 0.77 | HPGD (0.47) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL5437021 | 0.75 | SCN10A (0.52) | HPGDALDH1A1MAPTTDP1LMNA | |
| SCHEMBL5422107 | 0.75 | MKNK1 (0.58) | HPGDALDH1A1MAPTLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | claimed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | claimed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | claimed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | claimed |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-22 | — | — | US | disclosed |
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | HAVIV FORTUNA | 2007-02-08 | — | — | US | disclosed |
| EP-1551404-A2 | METHOD OF INHIBITING ANGIOGENESIS | Abbott Laboratories (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040116479-A1 | Method of inhibiting angiogenesis | ABBOTT LABORATORIES | 2004-06-17 | — | — | US | disclosed |
| WO-2004032908-A9 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LAB (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004032908-A2 | METHOD OF INHIBITING ANGIOGENESIS | ABBOTT LABORATORIES (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040067985-A1 | Method of inhibiting angiogenesis | ABBOT LABORATORIES | 2004-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032527-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | HPGD 158/4885ALDH1A1 837/4885MAPT 4443/4885 |
| US-20070043089-A1 | METHOD OF INHIBITING ANGIOGENESIS | PGF, VEGFA, FLT4 | HPGD 158/4885ALDH1A1 837/4885MAPT 4443/4885 |
| US-20040067985-A1 | Method of inhibiting angiogenesis | VEGFA, PGF, FLT4 | HPGD 149/4885ALDH1A1 450/4885MAPT 4658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.